Compare BNTC & TCPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BNTC | TCPC |
|---|---|---|
| Founded | 1995 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 344.4M | 337.3M |
| IPO Year | 2020 | 2006 |
| Metric | BNTC | TCPC |
|---|---|---|
| Price | $9.20 | $4.12 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 8 | 4 |
| Target Price | ★ $23.29 | $4.17 |
| AVG Volume (30 Days) | 177.7K | ★ 820.1K |
| Earning Date | 11-24-2026 | 11-05-2026 |
| Dividend Yield | N/A | ★ 16.39% |
| EPS Growth | ★ 6.67 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.89 | $3.08 |
| 52 Week High | $14.39 | $6.25 |
| Indicator | BNTC | TCPC |
|---|---|---|
| Relative Strength Index (RSI) | 49.46 | 48.42 |
| Support Level | $8.14 | $4.07 |
| Resistance Level | $9.29 | $4.24 |
| Average True Range (ATR) | 0.64 | 0.14 |
| MACD | 0.16 | -0.01 |
| Stochastic Oscillator | 53.62 | 39.42 |
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on advancing novel genetic medicines. Its technology could provide a one-shot cure for a wide range of diseases that require strict, ongoing treatment regimens or have no effective treatment or only palliative care options. The Company is developing a silence-and-replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life-threatening genetic disorder. The company has a single operating segment, which is the business of discovery and development of therapeutic agents for the treatment of genetic disorders.
BlackRock TCP Capital Corp is an externally-managed specialty finance company focused on middle-market lending. Its investment objective is to achieve high total returns through current income and capital appreciation, with an emphasis on principal protection. It seeks to achieve its investment objective through investments in debt securities of middle-market companies. The group generates returns through a combination of the receipt of contractual interest payments on debt investments and origination and similar fees, and, to a lesser extent, equity appreciation through options, warrants, conversion rights, or direct equity investments.